Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $49 | $53 | $46 | $57 |
| Short-Term Investments | $89 | $55 | $31 | $21 |
| Receivables | $46 | $40 | $42 | $42 |
| Inventory | $21 | $10 | $5 | $6 |
| Other Curr. Assets | $11 | $17 | $23 | $10 |
| Total Curr. Assets | $215 | $175 | $147 | $135 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $25 | $26 | $27 | $27 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $4 | $2 | $1 |
| Total NC Assets | $28 | $31 | $29 | $29 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $243 | $207 | $176 | $164 |
| Liabilities | – | – | – | – |
| Payables | $4 | $7 | $4 | $3 |
| Short-Term Debt | $30 | $23 | $15 | $8 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $31 | $1 | $28 |
| Other Curr. Liab. | $60 | $26 | $46 | $25 |
| Total Curr. Liab. | $94 | $87 | $67 | $63 |
| LT Debt | $31 | $38 | $46 | $52 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $45 | $45 |
| Total NC Liab. | $31 | $38 | $91 | $97 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $1 | $1 | $0 |
| Total Liabilities | $125 | $125 | $157 | $161 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,291 | -$1,319 | -$1,379 | -$1,390 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $1,409 | $1,401 | $1,397 | $1,393 |
| Total Equity | $118 | $82 | $19 | $3 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $243 | $207 | $176 | $164 |
| Net Debt | $12 | $8 | $15 | $3 |